Welcome to our dedicated page for Cara Therapeutics news (Ticker: CARA), a resource for investors and traders seeking the latest updates and insights on Cara Therapeutics stock.
Cara Therapeutics, Inc. (Nasdaq: CARA) is a pioneering biotechnology company focused on developing innovative treatments for pain, inflammation, and pruritus (itching). The company aims to address unmet medical needs with its proprietary therapeutic approaches and cutting-edge drug screening technology. Cara's flagship compound, CR845, is undergoing clinical trials for acute pain and uremic pruritus, demonstrating analgesic, anti-inflammatory, and antipruritic properties that could serve multiple therapeutic purposes.
Cara Therapeutics has recently made significant strides in its clinical programs. Despite the discontinuation of its clinical trial for pruritus associated with atopic dermatitis, the company remains optimistic about other late-stage clinical programs involving oral difelikefalin for indications such as notalgia paresthetica and chronic kidney disease. The company is also collaborating with HealthCare Royalty to secure financial backing and support for its ongoing and future developments.
Financially, Cara expects to end 2023 with approximately $100 million in cash, bolstered by milestone payments from HealthCare Royalty and efficient management of expenses. The company continues to focus on its goal of bringing first-in-class therapeutics to market, leveraging its proprietary drug-screening technology to expand its pipeline of innovative molecules targeting novel analgesic and anti-inflammatory pathways.
Cara Therapeutics, Inc. (Nasdaq: CARA) will host a conference call on March 1, 2022, at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results and provide company updates. The call will be accessible via phone or a live audio webcast on their website. Cara is focused on pruritus treatments and has FDA-approved KORSUVA™ (difelikefalin) for moderate-to-severe pruritus associated with chronic kidney disease. The company is also developing an oral version and plans to initiate Phase 3 programs in early 2022.
Cara Therapeutics (Nasdaq: CARA) has announced a virtual R&D event set for March 11, 2022, from 1:00 to 2:00 p.m. ET, focusing on the oral difelikefalin Phase 3 programs aimed at treating pruritus in patients suffering from atopic dermatitis and chronic kidney disease.
The event will feature key presenters, including CEO Christopher Posner and prominent medical professionals. A live audio webcast will be available on Cara's website, with a replay accessible afterward.
Cara Therapeutics announced the success of its licensor Maruishi Pharmaceutical in a Phase 3 study of difelikefalin injection for treating pruritus in hemodialysis patients. The trial achieved both primary and secondary endpoints, significantly reducing itch scores compared to placebo. Difelikefalin has shown good tolerance among patients. Following FDA approval in August 2021 for moderate-to-severe pruritus associated with chronic kidney disease, the U.S. launch is expected in Q2 2022. The European Medicines Agency is also reviewing its marketing application.
Cara Therapeutics (Nasdaq: CARA) announced that CEO Christopher Posner will present an overview at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 11:15 a.m. ET. The presentation will be available for live streaming and can be accessed from the company's website. Cara Therapeutics focuses on innovative treatments for pruritus, including KORSUVA™ (difelikefalin), the first FDA-approved therapy for chronic kidney disease-related pruritus. The company is also advancing an oral formulation of KORSUVA and has ongoing Phase 2 trials for additional conditions.
Cara Therapeutics (CARA) announced that the U.S. Centers for Medicare & Medicaid Services granted Transitional Drug Add-On Payment Adjustment (TDAPA) for its product KORSUVA (difelikefalin) injection, effective April 4, 2022, for two years. This approval facilitates reimbursement for new therapies in the end-stage renal disease category, aiding the upcoming commercial launch planned for early Q2 2022. KORSUVA, FDA-approved in August 2021, targets moderate-to-severe pruritus in chronic kidney disease patients on hemodialysis. This move supports access to innovative treatments for those in need.
Cara Therapeutics, Inc. (Nasdaq: CARA) announced participation in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. The chat will feature Christopher Posner, CEO, Thomas Reilly, CFO, and Joana Goncalves, M.D., CMO. A webcast of the event will be available on the company’s website and archived for approximately 30 days.
Cara, focused on alleviating pruritus through kappa opioid receptors, received FDA approval for KORSUVA Injection on August 23, 2021, targeting chronic kidney disease-related pruritus.
Cara Therapeutics, Inc. (Nasdaq: CARA) announced participation by CEO Christopher Posner in two investor conferences this November. The Stifel 2021 Virtual Healthcare Conference will host a fireside chat on November 15 at 1:20 p.m. ET, and the Jefferies London Healthcare Conference will feature a chat on November 18 at 3:00 a.m. ET. Webcasts will be accessible via the company's website and archived for 30 days. Cara Therapeutics focuses on developing treatments to alleviate pruritus through its innovative drug, KORSUVA, which recently received FDA approval for treating CKD-aP.
Cara Therapeutics announced the FDA approval of KORSUVA™ injection for treating chronic kidney disease-associated pruritus in hemodialysis patients, the first of its kind. CEO Christopher Posner will take over on November 9, 2021. The company reported a revenue increase to $20.3 million in Q3 2021, compared to $9.3 million in Q3 2020, alongside a net loss reduction to $1.0 million. R&D expenses decreased to $15.5 million. Cara expects its cash will be sufficient to fund operations through 2023. A conference call is set for 4:30 p.m. ET.
Cara Therapeutics appoints Christopher Posner as President and CEO effective November 9, 2021, succeeding Dr. Derek Chalmers, who moves to a Senior Advisor role. Posner, previously at LEO Pharma, brings over 23 years in global pharmaceutical management. The company is preparing to launch KORSUVA™ (difelikefalin), the first FDA-approved therapy for moderate-to-severe pruritus in hemodialysis patients, while also developing oral KORSUVA for conditions like atopic dermatitis. The transition aims to enhance execution of the commercial launch and overall strategic objectives.
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on alleviating pruritus through kappa opioid receptor targeting, will host a conference call on November 8, 2021, at 4:30 p.m. ET. The call will report Q3 2021 financial results and provide corporate updates. Participants can join by phone or via a live audio webcast available on the company's website. KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist, received FDA approval for treating moderate-to-severe pruritus associated with chronic kidney disease on August 23, 2021.
FAQ
What is the current stock price of Cara Therapeutics (CARA)?
What is the market cap of Cara Therapeutics (CARA)?
What does Cara Therapeutics, Inc. do?
What is CR845?
What are the properties of CR845?
What recent achievements has Cara Therapeutics made?
Why did Cara discontinue its clinical program for atopic dermatitis?
What are Cara's future plans?
How does Cara Therapeutics fund its projects?
What proprietary technology does Cara use?
What is the significance of oral difelikefalin?
How does Cara Therapeutics impact the biotechnology field?
